| (Values in U.S. Thousands) | Mar, 2023 | Sep, 2022 | Jun, 2022 | Mar, 2022 | Sep, 2021 |
| Sales | 266,000 | 299,000 | 307,000 | 299,000 | 284,000 |
| Sales Growth | -11.04% | -2.61% | +2.68% | +5.28% | -3.07% |
| Net Income | 47,000 | 59,000 | 4,000 | -107,000 | 47,000 |
| Net Income Growth | -20.34% | +1,375.00% | +103.74% | -327.66% | -12.96% |
Indivior Plc (INDV.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
Fiscal Year End Date: 12/31